|Bid||228.07 x 800|
|Ask||228.16 x 1100|
|Day's Range||227.58 - 231.03|
|52 Week Range||129.21 - 275.87|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||34.18|
|Earnings Date||Oct 26, 2021|
|Forward Dividend & Yield||3.40 (1.57%)|
|Ex-Dividend Date||May 13, 2021|
|1y Target Est||262.24|
New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) high risk early breast cancer will be presented at the October 14 European Society for Medical Oncology (ESMO) Virtual Plenary.
Our 2021 healthcare roundtable highlights the technologies and treatments changing the face of medicine, and the companies that could benefit.
Eli Lilly And Co (NYSE: LLY) has recalled one lot of an injectable prescription drug used to treat hypoglycemia, blood glucose levels that have dropped too low, which may occur in people with diabetes treated with insulin. The Company is recalling the lot following a complaint that a vial from this lot of Glucagon, D239382A, expiry date May 10, 2022, was found in liquid form instead of powder form. Glucagon typically comes in a powder form, accompanied by a diluting solution, and should be used